Chemexpress(SH:688131) Xin Lang Cai Jing·2025-09-22 03:02Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical has seen a stock price increase of 5.04%, reaching 77.51 yuan per share, with a total market capitalization of 16.44 billion yuan [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares in the second quarter, accounting for 2.1% of the fund's net value [2] - The fund has achieved a year-to-date return of 35.12%, ranking 2202 out of 8244 in its category, and a one-year return of 52.37%, ranking 2906 out of 8066 [2] - The fund manager, Xing Cheng, has been in position for 3 years and 185 days, with the fund's total asset size at 260 million yuan, achieving a best return of 81.15% and a worst return of -29.15% during his tenure [3]